ARMP: יחס מחיר להכנסות Armata Pharmaceuticals Inc

The calculated price-to-sales ratio reflects the dynamics of a patent-protected ecosystem of precision antimicrobial agents. The value 24.90 represents the current level of the metric, helping to assess overbought risks. Armata Pharmaceuticals (ARMP) is developing phage therapy for the lungs through collaborations with medical centers. Its status as a recognized expert in the fight against superbugs provides the brand with high credibility among investors and scientists.

For the biotech startup Armata Pharmaceuticals (ARMP), which has no commercial sales, the price-to-sales multiple loses its classical meaning due to the absence of revenue. This indicator compares market capitalization with sales volume to reflect the cost per unit of sales; however, with zero income and a high cash burn rate, this chart signals a speculative valuation and significant bankruptcy risks.